Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Institutional profile: University of Florida Health Personalized Medicine Program.

Literature DB >> 28346068

Institutional profile: University of Florida Health Personalized Medicine Program.

Larisa H Cavallari^1,2,3, Kristin W Weitzel^1,2,3, Amanda R Elsey^1,3, Xinyue Liu⁴, Scott A Mosley^1,2, Donald M Smith^1,2, Benjamin J Staley^4,5, Almut G Winterstein^4,6, Carol A Mathews⁷, Francesco Franchi⁸, Fabiana Rollini⁸, Dominick J Angiolillo⁸, Petr Starostik⁹, Michael J Clare-Salzler^3,9, David R Nelson^2,10, Julie A Johnson^1,2,3,10.

Abstract

The University of Florida (UF) Health Personalized Medicine Program launched in 2012 with CYP2C19 genotyping for clopidogrel response at UF Health Shands Hospital. We have since expanded CYP2C19 genotyping to UF Health Jacksonville and established the infrastructure at UF Health to support clinical implementation for five additional gene-drug pairs: TPMT-thiopurines, IFNL3 (IL28B)-PEG IFN-α-based regimens, CYP2D6-opioids, CYP2D6/CYP2C19-antidepressants and CYP2C19-proton pump inhibitors. We are contributing to the evidence based on outcomes with genotype-guided therapy through pragmatic studies of our clinical implementations. In addition, we have developed a broad array of educational programs for providers, trainees and students that incorporate personal genotype evaluation to enhance participant learning.

Entities: Chemical Gene Species

Keywords: PEG-interferon; clopidogrel; education; genotype; implementation; opioids; pharmacogenetics; proton pump inhibitors; selective serotonin uptake inhibitors; thiopurines

Mesh：

Year: 2017 PMID： 28346068 PMCID： PMC5558508 DOI： 10.2217/pgs-2017-0028

Source DB: PubMed Journal: Pharmacogenomics ISSN： 1462-2416 Impact factor: 2.533

11 in total

Review 1. The clinical importance of proton pump inhibitor pharmacokinetics.

Authors: B R Yacyshyn; A B R Thomson
Journal: Digestion Date: 2002 Impact factor: 3.216

2. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Authors: M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; T E Klein
Journal: Clin Pharmacol Ther Date: 2011-01-26 Impact factor: 6.875

3. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics.

Authors: Julie A Johnson; Amanda R Elsey; Michael J Clare-Salzler; David Nessl; Michael Conlon; David R Nelson
Journal: Pharmacogenomics Date: 2013-05 Impact factor: 2.533

4. Effects of Using Personal Genotype Data on Student Learning and Attitudes in a Pharmacogenomics Course.

Authors: Kristin Wiisanen Weitzel; Caitrin W McDonough; Amanda R Elsey; Benjamin Burkley; Larisa H Cavallari; Julie A Johnson
Journal: Am J Pharm Educ Date: 2016-09-25 Impact factor: 2.047

Review 5. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.

Authors: J K Hicks; J R Bishop; K Sangkuhl; D J Müller; Y Ji; S G Leckband; J S Leeder; R L Graham; D L Chiulli; A LLerena; T C Skaar; S A Scott; J C Stingl; T E Klein; K E Caudle; A Gaedigk
Journal: Clin Pharmacol Ther Date: 2015-06-29 Impact factor: 6.875

6. Clinical pharmacogenetics implementation: approaches, successes, and challenges.

Authors: Kristin W Weitzel; Amanda R Elsey; Taimour Y Langaee; Benjamin Burkley; David R Nessl; Aniwaa Owusu Obeng; Benjamin J Staley; Hui-Jia Dong; Robert W Allan; J Felix Liu; Rhonda M Cooper-Dehoff; R David Anderson; Michael Conlon; Michael J Clare-Salzler; David R Nelson; Julie A Johnson
Journal: Am J Med Genet C Semin Med Genet Date: 2014-03-10 Impact factor: 3.908

7. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.

Authors: A J Muir; L Gong; S G Johnson; M T M Lee; M S Williams; T E Klein; K E Caudle; D R Nelson
Journal: Clin Pharmacol Ther Date: 2013-10-04 Impact factor: 6.875

Review 8. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array.

Authors: J A Johnson; B M Burkley; T Y Langaee; M J Clare-Salzler; T E Klein; R B Altman
Journal: Clin Pharmacol Ther Date: 2012-08-22 Impact factor: 6.875

Review 9. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.

Authors: Mitsushige Sugimoto; Takahisa Furuta
Journal: World J Gastroenterol Date: 2014-06-07 Impact factor: 5.742

10. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.

Authors: Hui-Lin Tang; Yan Li; Yong-Fang Hu; Hong-Guang Xie; Suo-Di Zhai
Journal: PLoS One Date: 2013-04-30 Impact factor: 3.240

26 in total

Review 1. Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention.

Authors: Larisa H Cavallari
Journal: Expert Rev Cardiovasc Ther Date: 2017-07-19

Review 2. Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.

Authors: Simona Volpi; Carol J Bult; Rex L Chisholm; Patricia A Deverka; Geoffrey S Ginsburg; Howard J Jacob; Melpomeni Kasapi; Howard L McLeod; Dan M Roden; Marc S Williams; Eric D Green; Laura Lyman Rodriguez; Samuel Aronson; Larisa H Cavallari; Joshua C Denny; Lynn G Dressler; Julie A Johnson; Teri E Klein; J Steven Leeder; Micheline Piquette-Miller; Minoli Perera; Laura J Rasmussen-Torvik; Heidi L Rehm; Marylyn D Ritchie; Todd C Skaar; Nikhil Wagle; Richard Weinshilboum; Kristin W Weitzel; Robert Wildin; John Wilson; Teri A Manolio; Mary V Relling
Journal: Clin Pharmacol Ther Date: 2018-03-30 Impact factor: 6.875

Review 3. Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide.

Authors: Evangelia Eirini Tsermpini; Zeina N Al-Mahayri; Bassam R Ali; George P Patrinos
Journal: Hum Genet Date: 2021-10-01 Impact factor: 4.132

4. Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings.

Authors: Emily J Cicali; Kristin Wiisanen Weitzel; Amanda R Elsey; Frank A Orlando; Michelle Vinson; Scott Mosley; D Max Smith; Richard Davis; Lori Drum; David Estores; James P Franciosi; Melanie Gross Hagen; Gabriel J Jerkins; Elvira S Mercado; Jaison Nainaparampil; Adaixa Padron; Eric I Rosenberg; Ashleigh Wright; Siegfried O Schmidt; Carol A Mathews; Larisa H Cavallari; Julie A Johnson
Journal: Genet Med Date: 2019-03-30 Impact factor: 8.822

5. Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.

Authors: Philip E Empey; James M Stevenson; Sony Tuteja; Kristin W Weitzel; Dominick J Angiolillo; Amber L Beitelshees; James C Coons; Julio D Duarte; Francesco Franchi; Linda J B Jeng; Julie A Johnson; Rolf P Kreutz; Nita A Limdi; Kristin A Maloney; Aniwaa Owusu Obeng; Josh F Peterson; Natasha Petry; Victoria M Pratt; Fabiana Rollini; Stuart A Scott; Todd C Skaar; Mark R Vesely; George A Stouffer; Russell A Wilke; Larisa H Cavallari; Craig R Lee
Journal: Clin Pharmacol Ther Date: 2018-01-30 Impact factor: 6.875